vs
礼来（LLY）与摩根士丹利（MS）财务数据对比。点击上方公司名可切换其他公司
礼来的季度营收约是摩根士丹利的1.1倍（$19.3B vs $17.9B），礼来净利率更高（34.4% vs 24.6%，领先9.8%）
礼来（Eli Lilly and Company）是总部位于美国印第安纳州印第安纳波利斯的跨国制药企业，1876年由美国内战时期联邦军退伍药剂师伊莱·礼来创立，目前在18个国家设有办事处，产品销往全球约125个国家，是全球知名的制药厂商。
摩根士丹利是总部位于美国纽约曼哈顿中城百老汇1585号的跨国投资银行及金融服务提供商，在全球42个国家设有办事处，员工超8万名，服务客户涵盖企业、政府、机构及个人。2023年该公司位列美国财富500强第61位，同年位居福布斯全球2000强第30位。
LLY vs MS — 直观对比
营收规模更大
LLY
是对方的1.1倍
$17.9B
净利率更高
LLY
高出9.8%
24.6%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $19.3B | $17.9B |
| 净利润 | $6.6B | $4.4B |
| 毛利率 | 82.5% | — |
| 营业利润率 | 42.8% | 32.2% |
| 净利率 | 34.4% | 24.6% |
| 营收同比 | 42.6% | — |
| 净利润同比 | 50.5% | — |
| 每股收益（稀释后） | $7.39 | $2.68 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收LLYMS
| Q4 25 | $19.3B | $17.9B | ||
| Q3 25 | $17.6B | $18.2B | ||
| Q2 25 | $15.6B | $16.8B | ||
| Q1 25 | $12.7B | $17.7B | ||
| Q4 24 | $13.5B | — | ||
| Q3 24 | $11.4B | $15.4B | ||
| Q2 24 | $11.3B | $15.0B | ||
| Q1 24 | $8.8B | $15.1B |
净利润LLYMS
| Q4 25 | $6.6B | $4.4B | ||
| Q3 25 | $5.6B | $4.6B | ||
| Q2 25 | $5.7B | $3.5B | ||
| Q1 25 | $2.8B | $4.3B | ||
| Q4 24 | $4.4B | — | ||
| Q3 24 | $970.3M | $3.2B | ||
| Q2 24 | $3.0B | $3.1B | ||
| Q1 24 | $2.2B | $3.4B |
毛利率LLYMS
| Q4 25 | 82.5% | — | ||
| Q3 25 | 82.9% | — | ||
| Q2 25 | 84.3% | — | ||
| Q1 25 | 82.5% | — | ||
| Q4 24 | 82.2% | — | ||
| Q3 24 | 81.0% | — | ||
| Q2 24 | 80.8% | — | ||
| Q1 24 | 80.9% | — |
营业利润率LLYMS
| Q4 25 | 42.8% | 32.2% | ||
| Q3 25 | 41.1% | 33.1% | ||
| Q2 25 | 43.6% | 27.5% | ||
| Q1 25 | 27.2% | 31.3% | ||
| Q4 24 | 37.2% | — | ||
| Q3 24 | 13.9% | 27.4% | ||
| Q2 24 | 31.1% | 27.1% | ||
| Q1 24 | 28.9% | 29.0% |
净利率LLYMS
| Q4 25 | 34.4% | 24.6% | ||
| Q3 25 | 31.7% | 25.3% | ||
| Q2 25 | 36.4% | 21.1% | ||
| Q1 25 | 21.7% | 24.3% | ||
| Q4 24 | 32.6% | — | ||
| Q3 24 | 8.5% | 20.7% | ||
| Q2 24 | 26.3% | 20.5% | ||
| Q1 24 | 25.6% | 22.5% |
每股收益（稀释后）LLYMS
| Q4 25 | $7.39 | $2.68 | ||
| Q3 25 | $6.21 | $2.80 | ||
| Q2 25 | $6.29 | $2.13 | ||
| Q1 25 | $3.06 | $2.60 | ||
| Q4 24 | $4.88 | — | ||
| Q3 24 | $1.07 | $1.88 | ||
| Q2 24 | $3.28 | $1.82 | ||
| Q1 24 | $2.48 | $2.02 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $7.3B | $111.7B |
| 总债务越低越好 | — | $341.7B |
| 股东权益账面价值 | $26.5B | $111.6B |
| 总资产 | $112.5B | $1420.3B |
| 负债/权益比越低杠杆越低 | — | 3.06× |
8季度趋势，按日历期对齐
现金及短期投资LLYMS
| Q4 25 | $7.3B | $111.7B | ||
| Q3 25 | $9.9B | $103.7B | ||
| Q2 25 | $3.5B | $109.1B | ||
| Q1 25 | $3.2B | $90.7B | ||
| Q4 24 | $3.4B | — | ||
| Q3 24 | $3.5B | $91.1B | ||
| Q2 24 | $3.4B | $90.2B | ||
| Q1 24 | $2.6B | $102.3B |
总债务LLYMS
| Q4 25 | — | $341.7B | ||
| Q3 25 | — | $324.1B | ||
| Q2 25 | — | $320.1B | ||
| Q1 25 | — | $297.0B | ||
| Q4 24 | $29.5B | — | ||
| Q3 24 | — | $291.2B | ||
| Q2 24 | — | $269.9B | ||
| Q1 24 | — | $266.1B |
股东权益LLYMS
| Q4 25 | $26.5B | $111.6B | ||
| Q3 25 | $23.8B | $110.0B | ||
| Q2 25 | $18.3B | $108.2B | ||
| Q1 25 | $15.8B | $106.8B | ||
| Q4 24 | $14.2B | — | ||
| Q3 24 | $14.2B | $103.6B | ||
| Q2 24 | $13.6B | $100.7B | ||
| Q1 24 | $12.8B | $99.2B |
总资产LLYMS
| Q4 25 | $112.5B | $1420.3B | ||
| Q3 25 | $114.9B | $1364.8B | ||
| Q2 25 | $100.9B | $1353.9B | ||
| Q1 25 | $89.4B | $1300.3B | ||
| Q4 24 | $78.7B | — | ||
| Q3 24 | $75.6B | $1258.0B | ||
| Q2 24 | $71.9B | $1212.4B | ||
| Q1 24 | $63.9B | $1228.5B |
负债/权益比LLYMS
| Q4 25 | — | 3.06× | ||
| Q3 25 | — | 2.95× | ||
| Q2 25 | — | 2.96× | ||
| Q1 25 | — | 2.78× | ||
| Q4 24 | 2.08× | — | ||
| Q3 24 | — | 2.81× | ||
| Q2 24 | — | 2.68× | ||
| Q1 24 | — | 2.68× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $3.2B | $-2.4B |
| 自由现金流经营现金流 - 资本支出 | — | — |
| 自由现金流率自由现金流/营收 | — | — |
| 资本支出强度资本支出/营收 | — | — |
| 现金转化率经营现金流/净利润 | 0.49× | -0.55× |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流LLYMS
| Q4 25 | $3.2B | $-2.4B | ||
| Q3 25 | $8.8B | $-3.3B | ||
| Q2 25 | $3.1B | $11.8B | ||
| Q1 25 | $1.7B | $-24.0B | ||
| Q4 24 | $2.5B | — | ||
| Q3 24 | $3.7B | — | ||
| Q2 24 | $1.5B | — | ||
| Q1 24 | $1.2B | $4.4B |
现金转化率LLYMS
| Q4 25 | 0.49× | -0.55× | ||
| Q3 25 | 1.58× | -0.72× | ||
| Q2 25 | 0.55× | 3.34× | ||
| Q1 25 | 0.60× | -5.56× | ||
| Q4 24 | 0.56× | — | ||
| Q3 24 | 3.83× | — | ||
| Q2 24 | 0.49× | — | ||
| Q1 24 | 0.52× | 1.28× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
LLY
| Other | $5.4B | 28% |
| Zepbound | $4.2B | 22% |
| Mounjaro | $4.1B | 21% |
| Verzenio | $997.1M | 5% |
| Collaborationand Other Revenue | $991.7M | 5% |
| Taltz | $724.3M | 4% |
| Trulicity | $692.8M | 4% |
| Other Cardiometabolic Health | $524.5M | 3% |
| Other Oncology | $514.8M | 3% |
| Jardiance | $465.8M | 2% |
| Neuroscience | $320.2M | 2% |
| Other Immunology | $187.3M | 1% |
| Other Product Total | $77.0M | 0% |
MS
暂无分部数据
